| Symbol | VXRT |
|---|---|
| Name | VAXART, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 94080 United States CA 170 Harbor Way Suite 300 |
| Telephone | (650) 550-3500 |
| Fax | — |
| — | |
| Website | http://www.vaxart.com/ |
| Incorporation | US |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | WithumSmith+Brown; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0000072444 |
| Description | Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform. We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise. Additional info from OTC: |
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Read moreVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Read moreVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Read moreVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Read moreVaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Read moreVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Read moreVaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Read more